Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era
|
|
- Emma Clark
- 6 years ago
- Views:
Transcription
1 European Heart Journal (2005) 26, doi: /eurheartj/ehi101 Clinical research Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era Axel Bauer 1{, Przemyslaw Guzik 2{, Petra Barthel 1, Raphael Schneider 1, Kurt Ulm 3, Mari A. Watanabe 4, and Georg Schmidt 1 * 1 1. Medizinische Klinik der Technischen Universität München, Ismaninger Strasse 22, München, Germany 2 Department of Cardiology, University School of Medical Sciences, Poznan, Poland 3 Institut für Medizinische Statistik und Epidemiologie der Technischen Universität München, Germany 4 Department of Pharmacological and Physiological Science, St Louis University School of Medicine, St Louis, MO, USA Received 19 March 2004; revised 22 November 2004; accepted 30 November 2004; online publish-ahead-of-print 26 January 2005 See page 747 for the editorial comment on this article (doi: /eurheartj/ehi128) KEYWORDS Ventricular late potentials; Mortality; Myocardial infarction Aims To test the prognostic value of ventricular late potentials (LPs) in a large cohort of post-infarction patients in the modern reperfusion era. Methods and results 1800 consecutive survivors of acute myocardial infarction in sinus rhythm and under 76 years of age were enrolled. Many (99%) of the patients received reperfusion/revascularization therapy (91% percutaneous coronary intervention) and up-to-date pharmacological treatment (99% aspirin, 93% beta-blockers, 90% ACE-inhibitors, and 85% statins). LPs were calculated in 968 patients and found to be present in 90 (9.3%). The primary endpoint was the composite of cardiac death and serious arrhythmic events. The secondary endpoint was the composite of sudden cardiac death and serious arrhythmic events. During follow-up (median 34 months), 26 patients reached the primary endpoint. The presence of LPs was not significantly associated with the primary endpoint in univariable or multivariable analysis. In contrast, low (30%) left ventricular ejection fraction (hazard ratio 9.6, 95% confidence interval ), heart rate turbulence category 2 (7.5, ) and category 1 (5.3, ) were significant predictors in both univariable and multivariable analysis. Conclusion Ventricular LPs are of limited use for risk stratification in unselected postinfarction patients in the modern reperfusion era. Introduction The identification of post-infarction patients at high risk of subsequent death remains a challenge. 1 In recent years, many risk stratification methods have been evaluated, including ventricular late potentials (LPs). Most studies of the pre-thrombolytic era showed that both * Corresponding author. Tel: þ ; fax: þ address: gschmidt@tum.de { Both authors contributed equally to this work. arrhythmic events and cardiac death could be predicted by LPs, 2 5 although more recent studies have been inconclusive Modern therapeutic strategies, such as immediate revascularization by percutaneous coronary intervention and subsequent long-term administration of aspirin, beta-blockers, ACE-inhibitors, and statins, have substantially reduced both early and late mortality, and may be a major cause of the discrepancies between older and newer studies. At this time, the prognostic value of LPs in post-infarction patients receiving up-to-date & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oupjournals.org
2 756 A. Bauer et al. treatment is unknown. In this study, we therefore reevaluate the efficacy of ventricular LPs as a predictor of late cardiac mortality and serious arrhythmic events in a modern patient population. It is a retrospective analysis of a recent study conducted to validate a risk stratification protocol which included left ventricular ejection fraction (LVEF), heart rate turbulence (HRT), and several other risk predictors in survivors of recent myocardial infarction (MI). 13 Methods Recruitment and follow-up Patients of either sex, younger than 76 years of age, were enrolled between January 1996 and December 2000 if they had survived an acute MI within the last 4 weeks and were in sinus rhythm. Patients with bundle branch block morphology or marked intraventricular conduction delay (QRS duration 120 ms) in the standard ECG were excluded. Acute MI was diagnosed if there had been at least one episode of chest pain within the last 48 h lasting 20 min or longer, combined with either typical ECG changes (0.1 mv of ST segment elevation in 2 limb leads or 0.2 mv in 2 contiguous precordial leads) or with an increase of creatine kinase (CK) and its MB isoenzyme twice above the upper limit of normal. The institutional ethics committee approved the study protocol. Diabetes mellitus was considered present if a patient had been given this diagnosis and was receiving treatment (diet control, medication, or insulin), or if a blood glucose concentration of 11 mmol/l was repeatedly found. Minimum follow-up was 12 months with clinical appointments every 6 months. Patients who failed to meet these appointments were contacted by letter or telephone at corresponding intervals. Endpoints of the study In cases of death, the reasons for death were verified from hospital and autopsy records and from either the primary physicians or those who had witnessed the death. An endpoint committee defined the mode of death. Deaths were categorized as cardiac or non-cardiac deaths. In addition, cardiac deaths were categorized as sudden or non-sudden. Cardiac death was defined as sudden if it was (i) a witnessed death occurring within 60 min of the onset of new symptoms unless a cause other than cardiac was obvious, (ii) an unwitnessed death (,24 h) in the absence of pre-existing progressive circulatory failure or other causes of death, or (iii) death during attempted resuscitation. The primary endpoint of this study was the composite of cardiac death (sudden and non-sudden) and serious arrhythmic events [successful resuscitation, sustained symptomatic ventricular tachycardia, appropriate implantable cardioverter defibrillator (ICD) intervention]. The secondary endpoint tested was the composite of sudden cardiac death and serious arrhythmic events. Assessment of risk predictors In order to avoid a multiple test problem, we restricted our analyses to three risk predictors, namely LPs, LVEF, and HRT. All variables were measured during the second week after the index infarction. Ventricular LPs The signal-averaged ECG (SAECG) data were recorded by a commercially available Predictor w system (Dr Kaiser Medizintechnik, Bad Hersfeld, Germany). Silver silver chloride adhesive electrodes were fixed at standard Frank orthogonal X, Y, and Z leads. From each lead, a 300-ms segment was recorded that included the QRS complex and the ST segment. Two hundred cycles were averaged until a final noise level of,0.5 mv was reached. After analogue-to-digital conversion with a sampling rate of 2000 Hz and 16-bit accuracy, the three leads were bidirectionally filtered, with a high-pass filter set at 40 Hz, and combined into a vector magnitude: p ðx 2 þ y 2 þ z 2 Þ: ð1þ According to the Consensus Document on Signal-Averaged Electrocardiography, 14 ventricular LPs were considered as present when a QRS duration of.114 ms was accompanied by at least one of the following: root mean square of the terminal 40 ms of the filtered QRS, 20 mv; duration of the low-amplitude signal (,40 mv) in the terminal portion of the averaged QRS complex.38 ms. LVEF LVEF was assessed in single plane, 308 right anterior oblique projection technique using a digital angiographic system (Hicor, Siemens). LVEF was calculated by the area length method. In 81 patients, LVEF was assessed by single-plane echocardiography using a phased-array system (Sonos 2000 and Sonos 5500, Hewlett Packard, USA). Calculation of LVEF was based on a modified Simpson rule algorithm in the apical four-chamber view. LVEF was prospectively dichotomized at a value of 30%, where patients with LVEF 30% were defined as having low LVEF. The cut-off value of 30% for LVEF was chosen because it was used in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II 15 and in our previous post-infarction study. 13 HRT HRT was measured in 24-h Holter ECGs. The recordings were digitized at 128 Hz, and automatically processed using an Oxford Excel Holter system (Oxford Instruments, UK) or by a Pathfinder 700 system (Reynolds Medical, USA). The beat annotations (normal, ventricular ectopic, supraventricular ectopic, and unknown) were manually verified by an experienced technician. HRT categories 0, 1, and 2 were assigned according to previously published criteria. 13,16 Statistical analysis Continuous variables are presented as median and interquartile range (IQR) and qualitative data are expressed as percentages. The comparison of continuous variables was performed with the non-parametric Mann Whitney U test. Dichotomized data were analysed with the x 2 test or, in case of small numbers, with Fisher s exact test. Mortality rates were estimated by the Kaplan Meier method and compared using the log-rank test. The day of index infarction was defined as Day 0 of the follow-up period. Univariable and multivariable analyses were performed using the Cox proportional-hazards model. The proportional-hazards assumption was tested by means of Schoenfeld residuals using procedure stphtest in STATA (STATA, release 8.0) which is based on Grambsch and Thernau. 17 Multivariable models were adjusted for patient age 65 years (yes/no), sex, history of a previous MI (yes/no), and presence of diabetes (yes/no). Hazard ratios are given with 95% confidence intervals.
3 Prognostic power of ventricular late potentials 757 Table 1 Patient characteristics Patients with SAECG Patients without SAECG P n Age, years, median (IQR) 58 (51 66) 61 (53 68) Women, n (%) 193 (20) 220 (26) Diabetes mellitus, n (%) 142 (15) 162 (19) History of previous MI, n (%) 125 (13) 121 (15) 0.32 CK max U/L, median (IQR) 556 ( ) 513 ( ) LVEF, %, median (IQR) 57 (48 64) 57 (46 64) 0.67 LVEF 30%, n (%) 46 (5) 37 (4) 0.84 LVEF 40%, n (%) 121 (13) 89 (11) 0.31 QRS width, ms, median (IQR) 97 (80 100) 95 (80 100) 0.46 Table 2 Mortality, serious arrhythmic events, and endpoints in the study group Event Tests in the Cox model and log rank tests were two-sided. Differences were considered to be statistically significant when P, 0.05 (SPSS, Release 11.5, SPSS Inc.). Results Number of events Non-cardiac death Cardiac death Sudden cardiac death Appropriate ICD action Serious arrhythmic event Primary endpoint Secondary endpoint During the recruitment period, 1800 consecutive patients were enrolled. Of these patients, the actual study population consists of the 968 in whom SAECG was performed. In the remaining 832 cases, SAECG was missing for various reasons (no consent, early discharge, transfer to another hospital, or technically insufficient recordings). Clinical characteristics and therapy Cumulative event rate at 3 years (%) Table 1 depicts the clinical characteristics of the study population (in whom an SAECG was performed) and of excluded patients. In the study population, median age was 58 years, 20% were women, 15% were diabetic, and 13% had a history of a previous MI. The median of the creatine kinase maximum (CK max ) was 556 U/L. Median LVEF was 57%, 5% of the patients had an LVEF of 30% and 13% had an LVEF of 40%. The inclusion criteria of the Multicenter Unsustained Tachycardia Trial (MUSTT), 18 i.e. LVEF 40% and the presence of nonsustained ventricular tachycardia, were fulfilled by 1.9% of the patients. Excluded patients were older (61 years), more often female (26%), and suffered more frequently from diabetes mellitus (19%). Their median LVEF was identical to the study population at 57%. CK max was lower (513 vs. 556 U/L). In the study patients, percutaneous coronary intervention was performed in 91% of the patients (10% percutaneous transluminal coronary angioplasty alone, 81% percutaneous transluminal coronary angioplasty plus stenting), 6% received thrombolysis, and 2% underwent coronary artery bypass grafting. Thus, altogether, 99% of the patients received reperfusion/revascularization therapy. One per cent of the patients received none of these therapies because revascularization was deemed unnecessary or unreliable. Medication consisted of aspirin in 99%, beta-blockers in 93%, ACE-inhibitors in 90%, and statins in 85%. Thirty-six per cent of the patients were given diuretics. Follow-up and outcome Median follow-up period was 34 months, with an IQR of months. Six patients were lost to follow-up. They were censored at the date of latest contact. Three of the six patients belonged to the study population. The range of the follow-up periods for the six patients was days. Table 2 lists the cumulative rates of death and serious arrhythmic events together with the cumulative rates of primary and secondary endpoints for the study population. Out of 968 patients, 20 patients suffered a cardiac death (sudden and non-sudden) and eight experienced serious arrhythmic events or appropriate ICD shocks. In two patients who experienced appropriate ICD shocks, and who died from cardiac causes 12 and 26 months after the first shock, only the former events were taken into consideration, so that altogether 26 patients (2.7%) reached the primary endpoint. Out of 832 excluded patients, 35 patients (4.2%) reached the primary endpoint. With univariable Cox regression analysis, the difference was statistically significant with a hazard ratio of 1.67 ( , P ¼ 0.048). However, after adjustment for age, sex, diabetes, history of previous MI, LVEF, and QRS width, the risk of reaching the primary endpoint was almost evenly distributed with a hazard ratio of 1.37 ( , P ¼ 0.26).
4 758 A. Bauer et al. Table 3 Characteristics of patients with positive and negative LP LP-negative LP-positive P n Age, years, median (IQR) 58 (51 66) 58 (51 67) 0.95 Women, n (%) 185 (21) 8 (9) Diabetes mellitus, n (%) 128 (15) 14 (16) History of previous MI, n (%) 107 (12) 18 (20) CK max, U/L, median (IQR) 550 ( ) 556 ( ) 0.40 LVEF, %, median (IQR) 57 (48 64) 54 (42 62) LVEF 30%, n (%) 35 (4) 11 (12) LVEF 40%, n (%) 99 (11) 22 (24) QRS width, ms, median (IQR) 90 (80 100) 100 (90 100), Table 4 Association of risk variables with cardiac mortality and serious arrhythmic events in univariable and multivariable analysis Variable Hazard ratio (univariable) P Hazard ratio (multivariable) P LVEF 30% 18.7 ( ), ( ), HRT category 1 vs ( ), ( ) HRT category 2 vs ( ), ( ) LP (þ) vs. LP ( ) 2.3 ( ) ( ) 0.63 LVEF was used as a dichotomized variable. The multivariable analysis was adjusted for age of the patient, history of a previous MI, and the presence of diabetes mellitus. Association of risk predictors with mortality Ventricular LPs were present in 90 patients (9.3%). Table 3 depicts the clinical characteristics of patients with negative and positive LPs. The latter patients were characterized by a higher prevalence of males, a history of previous MI, a lower LVEF, and a broader QRS complex. The presence of LP was not significantly associated with the primary endpoint in either univariable or multivariable analysis (Table 4 ). In univariable analysis, the hazard ratio for a positive LP was 2.3 and not statistically significant (95% confidence interval , P ¼ 0.095). In contrast, the hazard ratio for LVEF 30% was 18.7 ( , P, ), and for HRT categories 1 and 2, it was 7.0 ( , P, ) and 18.1 ( , P, ), respectively. In multivariable analysis, only LVEF and HRT categories 1 and 2 were significant and independent predictors of the primary endpoint. Their hazard ratios were 9.6 ( , P, ), 5.3 ( , P ¼ ), and 7.5 ( , P ¼ ), respectively. None of the factors considered showed a statistically significant change of effect over time; that is, no deviation from the proportional hazards assumption was observed. To rule out the possibility that the loss of predictive ability of positive LPs in multivariable analysis was due to the use of dichotomized LVEF, we repeated the multivariable analysis with LVEF as a continuous variable. This was found not to affect the results of the study (Table 5 ). Figure 1 shows the cumulative rates of cardiac death and serious arrhythmic events for ventricular LPs, HRT categories, and LVEF groupings. In patients with positive LPs, the probability of reaching the primary endpoint at 3 years was 5.9% (five endpoints/90 patients) compared with 2.5% in patients with negative LPs (21 endpoints/ 878 patients). This difference did not reach statistical significance, whereas patients with poor HRT and LVEF had significantly higher mortality/arrhythmia rates than those with normal parameter values. In patients with HRT categories 0, 1, and 2, the endpoint probability was 0.9%, 6.2%, and 15.6%, respectively (P, ). In patients with LVEF. 30% and 30%, these figures were 1.6 and 27.3%, respectively (P, ). For LPs, the negative predictive value was 97.6%, which was significantly lower than that of LVEF (98.5%, P, 0.001) and HRT (99.1%, P, 0.05). We also analysed sudden cardiac death and serious arrhythmic events as a secondary endpoint. As Table 6 shows, the hazard ratio of LPs in the univariable analysis improved to 2.8 (as compared with 2.3 for primary endpoint), but not to the level of statistical significance (P ¼ 0.074). The hazard ratios of LVEF and HRT also improved. Discussion Our findings indicate that the predictive value of ventricular LPs for cardiac death, sudden and otherwise, and serious arrhythmic events has been lost or at least greatly reduced in the reperfusion era, when considering a generic post-mi population who present with sinus rhythm and normal QRS duration. On univariable analysis, the presence of LPs indicated a hazard ratio of 2.3 for the primary endpoint, with a significance level of P ¼ Therefore, a larger patient population may have
5 Prognostic power of ventricular late potentials 759 Table 5 Association of risk variables with cardiac mortality and serious arrhythmic events in univariable and multivariable analysis Variable Hazard ratio (univariable) P Hazard ratio (multivariable) P LVEF (continuous variable) 0.91 ( ), ( ), HRT category 1 vs ( ), ( ),0.002 HRT category 2 vs ( ), ( ),0.001 LP (þ) vs. LP ( ) 2.3 ( ) ( ) 0.69 LVEF was used as a continuous variable. The multivariable analysis was adjusted for age of the patient, history of a previous MI, and the presence of diabetes mellitus. Figure 1 Cumulative rate of cardiac death (CD) and serious arrhythmic events (SAE) stratified to negative and positive ventricular LPs (left panel), to HRT categories 0, 1, and 2 (medium panel), and to LVEF.30% and 30% (right panel). Numbers of patients at risk at 0, 12, and 24 months are shown under the graphs. produced a significant association. On multivariable analysis, however, the presence of LPs conveyed no prognostic power at all. This statement holds true not only for the primary endpoint, but also for the secondary endpoint of this study, namely the composite of sudden cardiac death and serious arrhythmic events. The first evidence for ventricular LPs was reported more than 20 years ago The prognostic significance of positive LPs in survivors of recent MI was evaluated in several studies. 2 5 The early studies of the prethrombolytic era consistently found that an abnormal SAECG indicated a significantly increased risk of sudden death, ventricular fibrillation, or sustained ventricular tachycardia. Later studies of the thrombolytic era do not find such a clear association. 22 The incidence of LP is lower, and this decrease has been paralleled by a decline in late mortality. In recent years it has been surmised that mechanical reperfusion of the infarction-related artery further contributes to the declining prevalence of ventricular LPs. 26 To our knowledge, this is the first study to evaluate the prognostic power of LPs in consecutive, i.e. unselected, post-infarction patients undergoing mechanical revascularization. On average, the infarction size was relatively small (median CK 556 U/L, median LVEF 57%) and LPs infrequent (9.3% of the patients). During the 3-year follow-up period, only 20 patients died from cardiac causes and only eight patients suffered serious arrhythmic events. Compared with previous postinfarction studies this figure is extremely low. It may be due to the high percentage of successful reperfusion and receipt of beta-blocker therapy, because both are known to significantly reduce the incidence of sudden cardiac death. With a decreasing number of endpoints, risk stratification becomes more and more difficult. 8,23 However, we do not think that the lack of prognostic power of LPs can be attributed solely to the low incidence of sudden cardiac death and serious arrhythmic events in our infarction population, because the two other predictors tested, namely impaired left ventricular function and abnormal HRT, both demonstrated strong predictive powers. Several publications have emphasized the high negative predictive value of ventricular LPs over other predictors. 14 Even this observation was not confirmed in our study. The negative predictive value of LPs was significantly lower than that of LVEF and of HRT. Because of the critical dependence of such values on chosen
6 760 A. Bauer et al. Table 6 analysis Association of risk variables with sudden cardiac death and serious arrhythmic events in univariable and multivariable Variable Hazard ratio (univariable) P Hazard ratio (multivariable) P LVEF 30% 21.8 ( ), ( ), HRT category 1 vs ( ), ( ) HRT category 2 vs ( ), ( ) LP (þ) vs. LP (2) 2.8 ( ) ( ) 0.50 LVEF was used as a dichotomized variable. The multivariable analysis was adjusted for age of the patient, history of a previous MI, and the presence of diabetes mellitus. thresholds of abnormality, we also repeated our analyses with other known criteria for the diagnosis of LPs, e.g. LPs positive if all three parameters are abnormal, or different cut-off values. Changing the criteria had no impact on the results. A relatively high number of patients was excluded because of missing SAECG. In order to detect or exclude a selection bias as the source of our findings, the clinical characteristics and the follow-up status of the excluded patients were compared with those of the study population. Excluded patients had a higher probability of reaching the primary endpoint with a hazard ratio of 1.67 ( , P ¼ 0.048). However, after adjustment for important clinical variables, this difference diminished almost completely [hazard ratio 1.37 ( , P ¼ 0.26)]. Thus, selection bias as an explanation for the lack of predictive power of ventricular LPs is not probable. Finally, LPs may well still be valid as a prognostic marker in selected high-risk patient populations, such as in patients with particular electrical abnormalities and poor ventricular function. 18,27 For example, the inclusion criteria for the MUSTT trial, i.e. the combination of an LVEF of 40% and the presence of nonsustained ventricular tachycardia, were met by only 18 out of 968 patients (1.9%). Therefore, we cannot extrapolate our results to patients with diagnosed ventricular tachyarrhythmias. Limitations The subjects included in this study were younger than 76 years of age. Thus, the results cannot be extrapolated to older post-infarction patients. Moreover, it is possible that techniques for the assessment of ventricular LPs different from those used in this study could have led to a better prediction of cardiac mortality and serious arrhythmic events. Conclusion We have shown that the presence of ventricular LPs is of little value for predicting cardiac death and serious arrhythmic events in generic post-infarction patient populations receiving modern reperfusion therapy. Acknowledgements This study was supported by grants from the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (no. 13N7073/7 to G.S.), from the Kommission für Klinische Forschung (to G.S.), and from the Deutsche Forschungsgemeinschaft (SFB 368 to K.U. and G.S.). References 1. Moss AJ. Dead is dead, but can we identify patients at increased risk for sudden cardiac death? J Am Coll Cardiol 2003;42: Breithardt G, Schwarzmaier J, Borggrefe M, Haerten K, Seipel L. Prognostic significance of late ventricular potentials after acute myocardial infarction. Eur Heart J 1983;4: Denniss AR, Richards DA, Cody DV, Russell PA, Young AA, Cooper MJ, Ross DL, Uther JB. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986;74: Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987;10: Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987;9: Pedretti R, Etro MD, Laporta A, Braga SS, Caru B. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993; 71: Hohnloser SH, Franck P, Klingenheben T, Zabel M, Just H. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. Circulation 1994;90: Kawalsky DL, Garratt KN, Hammill SC, Bailey KR, Gersh BJ. Effect of infarct-related artery patency and late potentials on late mortality after acute myocardial infarction. Mayo Clin Proc 1997;72: Touboul P, Andre-Fouet X, Leizorovicz A, Itti R, Lopez M, Sayegh Y, Milon H, Kirkorian G. Risk stratification after myocardial infarction. A reappraisal in the era of thrombolysis. The Groupe d Etude du Pronostic de l Infarctus du Myocarde (GREPI). Eur Heart J 1997;18: Savard P, Rouleau JL, Ferguson J, Poitras N, Morel P, Davies RF, Stewart DJ, Talajic M, Gardner M, Dupuis R, Lauzon C, Sussex B, Potvin L, Warnica W. Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997; 96:
7 Prognostic power of ventricular late potentials Tapanainen JM, Still AM, Airaksinen KE, Huikuri HV. Prognostic significance of risk stratifiers of mortality, including T wave alternans, after acute myocardial infarction: results of a prospective follow-up study. J Cardiovasc Electrophysiol 2001;12: Huikuri HV, Tapanainen JM, Lindgren K, Raatikainen P, Makikallio TH, Juhani Airaksinen KE, Myerburg RJ. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003;42: Barthel P, Schneider R, Bauer A, Ulm K, Schmitt C, Schomig A, Schmidt G. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 2003;108: Cain ME, Anderson JL, Arnsdorf MF, Mason JW, Scheinman MM, Waldo AL. ACC Consensus Document on Signal-Averaged Electrocardiography. J Am Coll Cardiol 1996;27: Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346: Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, Camm AJ, Bigger JT, Jr, Schomig A. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 1999;353: Grambsch P, Thernau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81: Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341: Berbari EJ, Scherlag BJ, Hope RR, Lazzara R. Recording from the body surface of arrhythmogenic ventricular activity during the S-T segment. Am J Cardiol 1978;41: Breithardt G, Seipel L, Ostermeyer J, Karbenn U, Abendroth RR, Borggrefe M, Yeh HL, Bircks W. Effects of antiarrhythmic surgery on late ventricular potentials recorded by precordial signal averaging in patients with ventricular tachycardia. Am Heart J 1982; 104: Simson MB, Untereker WJ, Spielman SR, Horowitz LN, Marcus NH, Falcone RA, Harken AH, Josephson ME. Relation between late potentials on the body surface and directly recorded fragmented electrograms in patients with ventricular tachycardia. Am J Cardiol 1983;51: Camm AJ. Programmed electrical stimulation, the signal-averaged electrocardiogram, and the implantable cardioverter-defibrillator in ventricular arrhythmias. Curr Opin Cardiol 1992;7: Gang ES, Lew AS, Hong M, Wang FZ, Siebert CA, Peter T. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 1989; 321: Zimmermann M, Adamec R, Ciaroni S. Reduction in the frequency of ventricular late potentials after acute myocardial infarction by early thrombolytic therapy. Am J Cardiol 1991;67: Karam C, Golmard J, Steg PG. Decreased prevalence of late potentials with mechanical versus thrombolysis-induced reperfusion in acute myocardial infarction. J Am Coll Cardiol 1996;27: Lomama E, Helft G, Persoz A, Vacheron A. Relation between successful late coronary angioplasty of an occluded, infarction-related artery and lower prevalence of ventricular late potentials. Coron Artery Dis 1998;9: Gomes JA, Cain ME, Buxton AE, Josephson ME, Lee KL, Hafley GE. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation 2001;104:
In the 2002 American College of Cardiology/American
Risk Stratification After Acute Myocardial Infarction by Heart Rate Turbulence Petra Barthel, MD; Raphael Schneider, Dipl Ing; Axel Bauer, MD; Kurt Ulm, PhD; Claus Schmitt, MD; Albert Schömig, MD; Georg
More information20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationSince their introduction in 1981, ventricular late potentials
Sudden Cardiac Death After Coronary Artery Bypass Grafting Is Not Predicted by Signal- Averaged ECG Christoph Scharf, MD, Hermann Redecker, MD, Firat Duru, MD, Reto Candinas, MD, Hans Peter Brunner-La
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: signal_averaged_ecg 7/1992 10/2017 10/2018 10/2017 Description of Procedure or Service Signal-averaged electrocardiography
More informationROLE OF THE SIGNAL ECG IN RISK STRATIFICATION OF SCD. An overview
ROLE OF THE SIGNAL ECG IN RISK STRATIFICATION OF SCD. An overview Nabil El-Sherif, MD SUNY - Downstate Medical Center & New York harbor VA Healthcare System Brooklyn, NY, USA Signal Averaged ECG: A Selective
More informationSluggish Upstroke of Signal-Averaged QRS Complex. An Arrhythmogenic Sign in Patients with Anteroseptal Myocardial Infarction
Original Article Sluggish Upstroke of Signal-Averaged QRS Complex. An Arrhythmogenic Sign in Patients with Anteroseptal Myocardial Infarction Masafumi Kanemura MD, Takao Katoh MD, Takashi Tanaka MD, Shin-ichiro
More informationMEDICAL POLICY POLICY TITLE T-WAVE ALTERNANS TESTING POLICY NUMBER MP
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY T-wave alternans is considered investigational as a technique
More informationDiabetes Care 34: , 2011
Pathophysiology/Complications O R I G I N A L A R T I C L E Reflex and Tonic Autonomic Markers for Risk Stratification in Patients With Type 2 Diabetes Surviving Acute Myocardial Infarction PETRA BARTHEL,
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationThe Multicenter Unsustained Tachycardia Trial (MUSTT)
Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial Kerry L. Lee, PhD; Gail Hafley, MS; John D. Fisher, MD; Michael R. Gold, MD; Eric
More informationJournal of the American College of Cardiology Vol. 44, No. 7, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 7, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.06.063
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationThe Immediate Reproducibility of T Wave Alternans During Bicycle Exercise
Reprinted with permission from JOURNAL OF PACING AND CLINICAL ELECTROPHYSIOLOGY, Volume 25, No. 8, August 2002 Copyright 2002 by Futura Publishing Company, Inc., Armonk, NY 10504-0418. The Immediate Reproducibility
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effectiveness of Implantable Cardioverter-Defibrillators in Patients With Ischemic Heart Disease and Left Ventricular Dysfunction Paul S. Chan, MD, MSc; Theodore Chow, MD; Dean Kereiakes,
More informationOriginal Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy
4 Original Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy Sirin Apiyasawat, Dujdao Sahasthas, Tachapong Ngarmukos, Pakorn Chandanamattha, Khanchit Likittanasombat
More informationCME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationT-Wave Alternans. Policy # Original Effective Date: 06/05/2002 Current Effective Date: 09/17/2014
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationjournal of medicine The new england Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
The new england journal of medicine established in 1812 june 23, 2005 vol. 352 no. 25 Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both Scott
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationClinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation
J Arrhythmia Vol 25 No 1 2009 Original Article Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation Seiji Takashio
More informationSignificance of QRS duration in non-st elevation myocardial infarction.
Thomas Jefferson University Jefferson Digital Commons Cardiology Faculty Papers Department of Cardiology 5-6-2015 Significance of QRS duration in non-st elevation myocardial infarction. Chinualumogu Nwakile
More informationNoninvasive Predictors of Sudden Cardiac Death
2011 년순환기관련학회춘계통합학술대회 Noninvasive Predictors of Sudden Cardiac Death 영남대학교의과대학순환기내과학교실신동구 Diseases associated with SCD Previous SCD event Prior episode of ventricular tachyarrhythmia Previous myocardial
More informationPause-induced Ventricular Tachycardia: Clinical Characteristics
Pause-induced Ventricular Tachycardia: Clinical Characteristics Margaret Bond A. Study Purpose and Rationale Until three decades ago, ventricular arrhythmias were thought to be rare in occurrence and their
More informationMEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationRelation of Ejection Fraction and Inducible Ventricular Tachycardia to Mode of Death in Patients With Coronary Artery Disease
Relation of Ejection Fraction and Inducible Ventricular Tachycardia to Mode of Death in Patients With Coronary Artery Disease An Analysis of Patients Enrolled in the Multicenter Unsustained Tachycardia
More informationSeveral studies of the primary prevention. Original Research
Original Research Hellenic J Cardiol 2015; 56: 230-236 Inducibility of Ventricular Arrhythmia and Tachyarrhythmia Recurrences in Patients with Implantable Defibrillator Giuseppe Stabile 1, Paolo Gallo
More information4/14/15. The Electrocardiogram. In jeopardy more than a century after its introduction by Willem Einthoven? Time for a revival. by Hein J.
The Electrocardiogram. In jeopardy more than a century after its introduction by Willem Einthoven? Time for a revival. by Hein J. Wellens MD 1 Einthoven, 1905 The ECG! Everywhere available! Easy and rapid
More informationDENNIS L. KUCHAR, MB, FRACP, CHARLES W. THORBURN, MB, FRACP, NEVILLE L. SAMMEL, MB, FRACP, FACC
JACC Vo!. 9. No.3 March 19X7:5,1 X 531 Prediction of Serious Arrhythmic Events After Myocardial Infarction: Signal-Averaged Electrocardiogram, Holter Monitoring and Radionuclide Ventriculography DENNIS
More informationELECTRO PHYSIOLOGIC STUDIES STEPHEN L. WINTERS, MD, FACC, DEBRA STEWART, RN, ADRIA TARGONSKI, MT, J. ANTHONY GOMES, MD, FACC
lacc Vol. 12, No.6 December 1988:1481-7 1481 ELECTRO PHYSOLOGC STUDES Role of Signal Averaging of the Surface QRS Complex in Selecting Patients With Nonsustained Ventricular Tachycardia and High Grade
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationHRV and Risk Stratification: Post-MI. Phyllis K. Stein, Ph.D. Washington University School of Medicine St. Louis, MO
HRV and Risk Stratification: Post-MI Phyllis K. Stein, Ph.D. Washington University School of Medicine St. Louis, MO Outline Research vs. clinical Holter scanning. Caveats in interpretation of published
More informationImplantable cardioverter defibrillator, Inappropriate shock, Lead failure
Inappropriate Discharges of Intravenous Implantable Cardioverter Defibrillators Owing to Lead Failure Takashi WASHIZUKA, 1 MD, Masaomi CHINUSHI, 1 MD, Ryu KAZAMA, 1 MD, Takashi HIRONO, 1 MD, Hiroshi WATANABE,
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationMicrovolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.026
More informationChapter 3. Eur Heart J 2009; 30:
Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Followup of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT) C. Jan Willem Borleffs, MD 1, Lieselot
More informationAre there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
More informationUse of Signal Averaged ECG and Spectral Analysis of Heart Rate Variability in Antiarrhythmic Therapy of Patients with Ventricular Tachycardia
October 1999 513 Use of Signal Averaged ECG and Spectral Analysis of Heart Rate Variability in Antiarrhythmic Therapy of Patients with Ventricular Tachycardia G.M. KAMALOV, A.S. GALYAVICH, N.R. KHASSANOV,
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationThe mortality of high-risk patients surviving myocardial
Arrhythmia/Electrophysiology Prevalent Low-Frequency Oscillation of Heart Rate Novel Predictor of Mortality After Myocardial Infarction Dan Wichterle, MD; Jan Simek, MD; Maria Teresa La Rovere, MD; Peter
More informationSignal-Averaged Electrocardiography
238 JACC Vol. 27, No. 1 ACC EXPERT CONSENSUS DOCUMENT Signal-Averaged Electrocardiography MICHAEL E. CAIN, MD, FACC, CHAIR JEFFREY L. ANDERSON, MD, FACC MORTON F. ARNSDORF, MD, FACC COMMITTEE MEMBERS JAY
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationJournal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationClinical Policy: Holter Monitors Reference Number: CP.MP.113
Clinical Policy: Reference Number: CP.MP.113 Effective Date: 05/18 Last Review Date: 04/18 Coding Implications Revision Log Description Ambulatory electrocardiogram (ECG) monitoring provides a view of
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More information03/17/16, 03/16/17, 03/15/18 CATEGORY: Technology Assessment. Proprietary Information of Excellus Health Plan, Inc.
MEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More information/13/$ - see front matter Ó 2013 Elsevier Inc. All rights reserved.
Volumetric Left Ventricular Ejection Fraction is Superior to 2-Dimensional Echocardiography for Risk Stratification of Patients for Primary Prevention Implantable Cardioverter-Defibrillator Implantation
More informationShocks burden and increased mortality in implantable cardioverter-defibrillator patients
Shocks burden and increased mortality in implantable cardioverter-defibrillator patients Gail K. Larsen, MD, MPH,* John Evans, MD, William E. Lambert, PhD,* Yiyi Chen, PhD,* Merritt H. Raitt, MD* From
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationCombination of QT Variability and Signalaveraged Electrocardiography in Association With Ventricular Tachycardia in Postinfarction Patients
Journal of Electrocardiology Vol. 36 No. 1 2003 Combination of QT Variability and Signalaveraged Electrocardiography in Association With Ventricular Tachycardia in Postinfarction Patients Gulmira Kudaiberdieva,
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationSIGNIFICANCE OF INDUCIBLE VENTRICULAR FLUTTER - FIBRILLATION AFTER MYOCARDIAL INFARCTION.
! 1 SIGNIFICANCE OF INDUCIBLE VENTRICULAR FLUTTER - FIBRILLATION AFTER MYOCARDIAL INFARCTION. Béatrice Brembilla-Perrot Cardiology, CHU of Brabois, Vandoeuvre, France Adress for correspondence : B Brembilla-Perrot,
More informationECTOPIC BEATS: HOW MANY COUNT?
ECTOPIC BEATS: HOW MANY COUNT? Rupert FG Simpson, 1 Jessica Langtree, 2 *Andrew RJ Mitchell 2 1. King s College Hospital, London, UK 2. Jersey General Hospital, Jersey, UK *Correspondence to mail@jerseycardiologist.com
More informationMicrovolt T-wave alternans during exercise and pacing are not comparable
Europace (2009) 11, 1375 1380 doi:10.1093/europace/eup253 CLINICAL RESEARCH T Wave Alternans Microvolt T-wave alternans during exercise and pacing are not comparable Karin Kraaier 1, Patrick M.J. Verhorst
More informationManagement of Ventricular Arrhythmias A Trial-based Approach
Journal of the American College of Cardiology Vol. 34, No. 3, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00273-9 REVIEW
More informationAtrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients
Europace (2006) 8, 566 572 doi:10.1093/europace/eul081 Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients Marcelle D. Smit, Pascal F.H.M.
More informationCurrent guidelines for device-based therapy of cardiac
Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II Ilan Goldenberg,
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationIntroduction. CLINICAL RESEARCH Clinical Trial Design. Mohammad Saeed 1 *, Mehdi Razavi 1, Curtis G. Neason 2, and Simona Petrutiu 2. Aims.
Europace (2011) 13, 1648 1652 doi:10.1093/europace/eur195 CLINICAL RESEARCH Clinical Trial Design Rationale and design for programming implantable cardioverter defibrillators in patients with primary prevention
More informationPrimary PCI versus thrombolytic therapy: long-term follow-up according to infarct location
Heart Online First, published on April 14, 2005 as 10.1136/hrt.2005.060152 1 Primary PCI versus thrombolytic therapy: long-term follow-up according to infarct location Short running head: Anterior infarction
More informationMichel Mirowski and colleagues ABSTRACT CARDIOLOGY. ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death
ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death Ronald D. Berger, MD, PhD, FACC ABSTRACT PURPOSE: To review recent major randomized trials of implantable
More informationVolume 141, UTILITY OF SHORT-TERM HEART RATE VARIABILITY FOR PREDICTION OF SUDDEN CARDIAC DEATH AFTER ACUTE MYOCARDIAL INFARCTION
Volume 141, 1998 69 UTILITY OF SHORT-TERM HEART RATE VARIABILITY FOR PREDICTION OF SUDDEN CARDIAC DEATH AFTER ACUTE MYOCARDIAL INFARCTION Josef Kautzner a, Petr Šťovíček b, Zdeněk Anger b, Jarmila Šavlíková
More informationRita Calé, Miguel Mendes, António Ferreira, João Brito, Pedro Sousa, Pedro Carmo, Francisco Costa, Pedro Adragão, João Calqueiro, José Aniceto Silva.
Peak Circulatory Power : a new parameter of cardiopulmonary exercise testing to predict arrhythmic events in patients with implantable cardioverter defibrillator for primary prevention Rita Calé, Miguel
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationNon-invasive sudden death risk stratification
Non-invasive sudden death risk stratification Roberto F.E. Pedretti, Simona Sarzi Braga Division of Cardiology, IRCCS S. Maugeri Foundation, Scientific Institute of Tradate, Tradate (VA), Italy Key words:
More informationAbbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1
2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic
More informationQT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy
European Heart Journal (1996) 17, 258-263 QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy L. Fei, J. H. Goldman,
More informationEvaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias. Markus Kowalsky Group 11
Evaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias Markus Kowalsky Group 11 Selected Paper Ventricular arrhythmia is predicted by sum absolute QRST integral but not
More informationMy Patient Needs a Stress Test
My Patient Needs a Stress Test Amy S. Burhanna,, MD, FACC Coastal Cardiology Cape May Court House, New Jersey Absolute and relative contraindications to exercise testing Absolute Acute myocardial infarction
More informationUse of Electrophysiologic Testing in Patients With Nonsustained Ventricular Tachycardia Prognostic and Therapeutic Implications
JACC Vol. 14, No. I July 1 8 1 5 5-61 155 ELECTROPHYSIOLOGIC STUDIES Use of Electrophysiologic Testing in Patients With Nonsustained Ventricular Tachycardia Prognostic and Therapeutic Implications RICHARD
More informationEXPERT CONSENSUS DOCUMENT
EXPERT CONSENSUS DOCUMENT American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More informationThe International Classification of Diseases, Tenth Revision,
AHA/ACCF/HRS Scientific Statement American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying
More informationHeart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials
Journal of Cardiac Failure Vol. 8 No. 3 2002 Perspectives Heart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials LESLIE A. SAXON,
More informationGE Healthcare. The GE EK-Pro Arrhythmia Detection Algorithm for Patient Monitoring
GE Healthcare The GE EK-Pro Arrhythmia Detection Algorithm for Patient Monitoring Table of Contents Arrhythmia monitoring today 3 The importance of simultaneous, multi-lead arrhythmia monitoring 3 GE EK-Pro
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationThe noninvasive identification of individuals at risk for
Analysis of 12-Lead T-Wave Morphology for Risk Stratification After Myocardial Infarction Markus Zabel, MD; Burak Acar, PhD; Thomas Klingenheben, MD; Michael R. Franz, MD, PhD; Stefan H. Hohnloser, MD;
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationInteractive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators
22 March 2002 Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators F. HINTRINGER, O. PACHINGER Division of Cardiology, Department for Internal Medicine, University
More informationPREDICTION AND STRATIFICATION OF THE FUTURE CARDIOVASCULAR ARRHYTHMIC EVENTS: SIGNAL AVERAGED ELECTROCARDIOGRAPHY VERSUS EJECTION FRACTION*
Indian J Physiol Pharmacol 2010; 54 (2) : 123 132 PREDICTION AND STRATIFICATION OF THE FUTURE CARDIOVASCULAR ARRHYTHMIC EVENTS: SIGNAL AVERAGED ELECTROCARDIOGRAPHY VERSUS EJECTION FRACTION* ANIL KUMAR
More informationOriginal Article Risk of Death and Recurrent Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial Infarction
www.ipej.org 5 Original Article Risk of Death and Recurrent Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial Infarction Ish Singla MD*, Haitham Hreybe MD*, Samir
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationIntroduction. CLINICAL RESEARCH Sudden death and ICDs
Europace (14) 16, 1315 1321 doi:.93/europace/euu26 CLINICAL RESEARCH Sudden death and ICDs What is the optimal left ventricular ejection fraction cut-off for risk stratification for primary prevention
More information/$ -see front matter 2011 Heart Rhythm Society. All rights reserved. doi: /j.hrthm
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram Ben-Gal T, Zafrir
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationPractitioner Education Course
2015 Practitioner Education Course ST Elevation Myocardial Infarction 2 Pathology Concept of vulnerable plaque Mild Atheroma Diagnosis IVUS OCT 3 Diagnosis This is based on : Clinical History ECG Changes.
More informationAutomatic Identification of Implantable Cardioverter-Defibrillator Lead Problems Using Intracardiac Electrograms
Automatic Identification of Implantable Cardioverter-Defibrillator Lead Problems Using Intracardiac Electrograms BD Gunderson, AS Patel, CA Bounds Medtronic, Inc., Minneapolis, USA Abstract Implantable
More information